Impact Analysis of the Decline in the Traditional Chinese Medicine Injection Industry on Yu Kang Pharmaceutical (600658.SH)

Based on public information, the decline in the TCM injection industry has a significant impact on Yu Kang Pharmaceutical (600658.SH), but it needs to be analyzed from multiple dimensions:

Yu Kang Pharmaceutical is a pharmaceutical company with

. Its main products include:

• Ginkgo Biloba Extract Injection
  (trade name: Yue Kang Tong)
• Other TCM injection products

The company’s product structure is relatively concentrated, and TCM injections occupy an important position in its revenue [0].

In recent years, the state has tightened regulation on TCM injections:

• Higher drug approval standards
• Increased restrictions on clinical use
• Strengthened requirements for adverse reaction monitoring
• Pressure from medical insurance payment control

• The growth rate of the overall market size of TCM injections has slowed down
• Some provinces restrict the use of TCM injections in primary medical institutions
• Narrowed clinical application scenarios

• May face pressure on product sales growth
• Gross profit margin may be affected to some extent
• Need to cope with the pain of the industry adjustment period

In the face of industry changes, Yu Kang Pharmaceutical may take the following response measures:

1. Product Structure Adjustment
   • Increase R&D investment in chemical drugs and biological drugs
   • Expand product lines of other dosage forms such as oral preparations

2. Quality Upgrading
   • Improve product quality standards
   • Strengthen safety research
   • Improve evidence-based medicine evidence

3. Market Expansion
   • Explore the out-of-hospital market
   • Explore international market opportunities
   • Strengthen academic promotion

The impact of the decline in the TCM injection industry on Yu Kang Pharmaceutical mainly includes:

• Short-term performance fluctuation risk
  : The industry policy adjustment period may affect the company’s performance
• Valuation pressure
  : Market concerns about the prospects of the TCM injection industry may suppress valuation
• Transformation uncertainty
  : Business transformation requires time and resource investment

The impact of the decline in the TCM injection industry on Yu Kang Pharmaceutical is

, but the degree of impact depends on the company’s response strategies and transformation effectiveness. As an investor, you should focus on the company’s:

• Progress of product structure adjustment
• New product R&D pipeline
• Performance stability
• Valuation rationality

It is recommended that investors continuously track the company’s development dynamics in combination with the company’s regular reports and industry policy changes.

---

Note: The above analysis is based on public information collation. Please refer to the company’s announcements for specific data. It is recommended that investors pay attention to the company’s latest announcements for accurate information.